The Drugs Controller General of India (DCGI) has recommended that Serum Institute of India’s Covid vaccine Covovax be approved for use as a heterologous booster dose for those who have already received two doses of Covishield or Covaxin.
Previously, DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, for children aged 12 to 17 on March 9, 2022, and for children aged 7 to 11 on June 28, 2022, subject to certain conditions. Covovax is made possible by a technology transfer from Novavax. It has received conditional marketing authorization from the European Medicines Agency.
On December 17, 2021, the World Health Organization (WHO) granted it an emergency-use listing.
The Government of India recently approved Bharat Biotech’s nasal Covid vaccine for adults over the age of 18 for use as a heterologous booster dose.
Private hospitals will be able to obtain the vaccine.